14th week of 2022 patent applcation highlights part 20 |
Patent application number | Title | Published |
20220106336 | Heterocyclic Compound, Light-Emitting Element, Light-Emitting Device, Electronic Device, And Lighting Device - Provided are a heterocyclic compound which emits blue light and is represented by General Formula (G1) below, and a light-emitting element, a light-emitting device, an electronic device and a lighting device which are formed using the heterocyclic compound represented by General Formula (G1) below. The use of the heterocyclic compound represented by General Formula (G1) makes it possible to provide a light-emitting element which has high emission efficiency, and also a light-emitting device, an electronic device and a lighting device which have reduced power consumption. | 2022-04-07 |
20220106337 | BRANCHED ORGANOSILICON COMPOUND, METHOD OF PREPARING SAME, AND COMPOSITIONS COMPRISING SAME - A branched organosilicon compound is provided which has the general formula (R | 2022-04-07 |
20220106338 | Systems and Methods for Mechanosynthesis - Systems and methods for mechanosynthesis are disclosed, including those that avoid the need for a bootstrap process, avoid the need to build tips via mechanosynthesis, avoid the need for charging tips with feedstock during a build sequence, avoid the need to dispose of reaction byproducts, which reduce the design complexity of new tips, and/or which reduce or avoid the need for multiple positional means and/or tip switching. | 2022-04-07 |
20220106339 | Methods of Making High Enantioselective Secondary Alcohols - A new process to synthesis of compound OBI-3424 R-form and S-form products is provided. The “R-form” compound OBI-3423 was first synthesized with 48% overall yield from compound OBI-3424-5 by installation of the labile phosphate motif at later stage. The stereo chemistry is established by 5 steps chemo-enzyme combination synthesis to afford 99% optical purity. After then, the “S-form” compound OBI-3424 is prepared with improving overall yield of 54% from compound OBI-3424-5. The stereo chemistry is established by 4 steps combination of chemo-enzyme synthesis with excellent optical purity of 99%. | 2022-04-07 |
20220106340 | ACYLPHOSPHINE OXIDE COMPOUNDS AND PREPARATION METHODS THEREOF - Disclosed are an acylphosphine oxide compound and a preparation method therefor, which belong to the field of initiators. The method comprises: reacting compound B and compound C under the conditions of an organic base and an organic solvent so as to obtain the acylphosphine oxide compound. The chemical structural formula of compound B is as follows: | 2022-04-07 |
20220106341 | PROCESS FOR PREPARING FOSTEMSAVIR - A method for the preparation of a compound of Formula IV | 2022-04-07 |
20220106342 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES - Provided are Platinum and Iridium complexes with spiro[ | 2022-04-07 |
20220106343 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES - Provided are organometallic compounds including a ligand L | 2022-04-07 |
20220106344 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES - A compound including a first ligand L | 2022-04-07 |
20220106345 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND DIAGNOSTIC COMPOSITION INCLUDING THE ORGANOMETALLIC COMPOUND - Provided are an organometallic compound represented by Formula 1, an organic light-emitting device including the organometallic compound, and a diagnostic composition including the organometallic compound: | 2022-04-07 |
20220106346 | ORGANOMETALLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME - Provided are an organometallic compound represented by Formula 1 and an organic light-emitting device including the same. The organic light-emitting device includes a first electrode; a second electrode facing the first electrode; an organic layer between the first electrode and the second electrode and including an emission layer; and at least one organometallic compound represented by Formula 1. | 2022-04-07 |
20220106347 | POROUS INORGANIC CARRIER AND METHOD FOR PRODUCING NUCLEIC ACID USING SAME - An inorganic porous carrier including a linker of formula (1), wherein a mode diameter in a pore distribution is 0.04 μm to 1 μm, and a predetermined cumulative pore volume ratio is 30% or less [a bond * represents a linkage to the oxygen atom of a silanol group in an inorganic porous substance; n is an integer; R represents independently of each other an alkyl group containing 3 to 10 carbon atoms which may optionally have a substituent such as an alkoxy group; and L represents a single bond; an alkylene group of 1 to 20 carbon atoms; or an alkylene group containing 2 to 20 carbon atoms which contains —CH | 2022-04-07 |
20220106348 | N-ACETYLATED SIALIC ACIDS AND RELATED SIALOSIDES - The present invention provides N-acetyl derivatives of sialic acids, including N-acetyl derivatives of Neu5Ac and Neu5Gc. Methods for preparing related precursors and a variety of sialosides are also disclosed. | 2022-04-07 |
20220106349 | Compounds - The invention provides novel compounds that are derivatives of Azithromycin and that have been found by the current inventors to have low antimicrobial activity but significant epithelial barrier enhancement properties. The invention further provides use of the compounds as a medicament, in particular in the treatment or prophylaxis of a disease or condition that is caused by a defect in epithelial cells or tissue, or a disease or condition that benefits from enhancement or restoration of epithelial barrier function, for example diseases of the respiratory tract. | 2022-04-07 |
20220106350 | EFFICIENT AND SCALABLE SYNTHESES OF NICOTINOYL RIBOSIDES AND REDUCED NICOTINOYL RIBOSIDES, MODIFIED DERIVATIVES THEREOF, PHOSPHORYLATED ANALOGS THEREOF, ADENYLYL DINUCLEOTIDE CONJUGATES THEREOF, AND NOVEL CRYSTALLINE FORMS THEREOF - The present disclosure provides methods of making nicotinoyl riboside compounds or derivatives of formula (I): | 2022-04-07 |
20220106351 | HETERODIMER COMPOSITIONS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS - Described herein are processable compositions comprising at least one moiety that is processable in its free form. Also described herein are compositions and methods for the treatment of ocular diseases or disorders including glaucoma, blepharitis, ocular inflammation, diabetic macular edema, posterior inflammation, anterior inflammation, macular degeneration (e.g., wet macular degeneration (AMD) or dry AMD), post-cataract surgery, and retinal vein occlusion. Said compositions and methods comprise steroids and prostaglandins which demonstrate anti-inflammatory activity, intraocular pressure (IOP) lowering, and/or other desirable activities. Injection of said compositions in the eye provides therapeutic benefit to patients suffering from ocular disorders. | 2022-04-07 |
20220106352 | PROCESS FOR THE PREPARATION OF FULVESTRANT 3-BORONIC ACID - A process for the preparation of fulvestrant 3-boronic acid and intermediates useful for the preparation of fulvestrant 3-boronic acid according to the process are described. Fulvestrant 3-boronic acid is obtained with high purity. | 2022-04-07 |
20220106353 | PROCESS - An efficient and commercial phosphorylation process of a complex alcohol, such as secondary and tertiary alcohols, with P | 2022-04-07 |
20220106354 | GLYCYRRHETINIC ACID DERIVATIVES FOR USE IN TREATING HYPERKALEMIA - The present invention provides a compound of formula (I) or a salt thereof: (Formula (I)) wherein X, L, V, R | 2022-04-07 |
20220106355 | METHOD FOR PRODUCING PEPTIDE COMPOUND - The invention provides a method for producing a peptide which comprises the following steps (1) and (2): (1) a step of condensing a C-protected amino acid or a C-protected peptide to a C-terminal of an N-protected amino acid or an N-protected peptide represented by the formula (I): | 2022-04-07 |
20220106356 | CHEMOSELECTIVE THIOL-CONJUGATION WITH ALKENE OR ALKYNE-PHOSPHONAMIDATES - Disclosed are novel conjugates and processes for the preparation thereof. A process for the preparation of alkene- or alkyne-phosphonamidates comprises the steps of
| 2022-04-07 |
20220106357 | PLASMA FRACTIONATION UTILIZING SPRAY-DRIED HUMAN PLASMA - The present invention provides a method of fractionating human plasma, in some embodiments, using the Cohn fractionation procedure. The improvement comprises the use of physiologically active reconstituted spray dried human plasma as the starting material for the fractionation procedure. | 2022-04-07 |
20220106358 | CONTINUOUS VIRUS RETENTIVE FILTRATION - The present application provides methods and systems for viral clearance for purifying an antibody from a sample comprising one or more impurities including viral particles. The method is conducted in a system which includes a hydrophobic interaction chromatography (HIC) column and a virus retentive filtration (VRF) system. The HIC column and the VRF system are connected inline in a continuous processing system, and the VRF system comprises at least two filter trains in parallel. | 2022-04-07 |
20220106359 | INHIBITORS OF NF KAPPA-B ACTIVITY FOR TREATMENT OF DISEASES AND DISORDERS - Peptides and methods of use thereof, are disclosed for use in treating various disease and disorders, including inflammation, pain, oral mucositis, oral lesions, and cancer. The Peptides modulate the activity of the transcription factor NF κB. | 2022-04-07 |
20220106360 | NEUROPROTECTIVE PEPTIDES AND METHODS OF THEIR USE - Neuroprotective peptides derived from the voltage-gated potassium channel Kv2.2 are described. The peptides promote dispersal of the cognate channel Kv2.1 in neurons, thereby blocking pro-apoptotic potassium efflux, and preserving cell viability after apoptotic injury. Methods of preventing and treating neuronal damage, such as neuronal damage following ischemic stroke, by administering the neuroprotective peptides are described. Fusion of the neuroprotective peptides to a cell-penetrating peptide to promote cellular uptake is also described. | 2022-04-07 |
20220106361 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF - Provided, inter alia, are macrocyclic compounds. | 2022-04-07 |
20220106362 | SELENIUM-BASED THERAPIES - This invention relates to methods of administering compounds containing selenium, selenocysteine, or a selenocysteine peptide to treat, for example, conditions associated with selenium deficiency, or ferroptoptic, parthanototic, and endoplasmic reticulum stress, and/or cancer. The methods of treatment may activate or inhibit (via TFAP2C and Sp1 proteins) the adaptive homeostatic response of the selenome. The compounds may contain a targeting sequence that causes them to be delivered to specific organs and/or tissues. The compounds may be administered, for example, orally, intranasally, intravenously, or by a minimally invasive catheter or BrainPath. | 2022-04-07 |
20220106363 | CHIMERIC PROTEIN FOR CORONAVIRUS VACCINE - The disclosure relates to a polypeptide comprising, or consisting of, the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 9 or a sequence having at least 97%-100% sequence identity to one of SEQ ID NO: 1, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 9 for use as an immunogen for the purpose of eliciting an immune response in a subject susceptible to infection with a coronavirus. The disclosed polypeptide is further useful in reducing the severity of symptoms associated with a coronavirus infection. In addition to use in a protein-based vaccine, the polypeptide of the disclosure can be encoded by a nucleic acid/ribonucleic acid and used in a nucleic acid vaccine or viral vector vaccine. | 2022-04-07 |
20220106364 | COMPLEXES OF CYTOMEGALOVIRUS PROTEINS - An isolated human cytomegalovirus (HCMV) membrane protein complex that comprises gH, gL and at least one more HCMV glycoprotein is provided. In some embodiments the complex consists of gH, gL and gO. In other embodiments the complex consists of gH, gL, pUL128, pUL130 and pUL131A. Processes for expressing and purifying such complexes, and subsequent uses of such complexes in immunogenic compositions and vaccines, are also provided. | 2022-04-07 |
20220106365 | PROTEINS FOR THE TREATMENT OF EPITHELIAL BARRIER FUNCTION DISORDERS - The disclosure relates to therapeutic proteins and pharmaceutical compositions comprising said proteins, which have utility in treating various human diseases. In particular aspects, the disclosed therapeutic proteins are useful for treating human gastrointestinal inflammatory diseases and gastrointestinal conditions associated with decreased epithelial cell barrier function or integrity. Further, the disclosed therapeutic proteins are useful for treating human inflammatory bowel disease, including inter alia, Crohn's disease and ulcerative colitis. | 2022-04-07 |
20220106366 | RAMA TRANSCRIPTION FACTOR MUTANT FOR PROMOTING PRODUCTION OF N-ACETYLGLUCOSAMINE AND USE THEREOF - The present invention discloses a RamA transcription factor mutant for promoting the production of N-acetylglucosamine and use thereof. The mutant is obtained by mutating lysine at position 90 to asparagine and serine at position 92 to lysine in a parent having an amino acid sequence as shown in SEQ ID NO: 2. The present invention provides a genetically engineered strain that overexpresses the RamA transcription factor mutant and increases the production of N-acetylglucosamine. By overexpressing the transcription factor RamA that is involved in the regulation of carbon metabolism, the extracellular accumulation of N-acetylglucosamine is increased, with a maximum concentration reaching 31.5 g/L, which lays a foundation for further metabolic engineering of | 2022-04-07 |
20220106367 | PREPARATION AND USE OF GINSENTIDES AND GINSENTIDE-LIKE PEPTIDES - The present invention relates to the methods of solid-phase peptide synthesis or recombinant production of ginsentide or ginsentide-like peptides or salts thereof. Further provided are uses of the ginsentide or ginsentide-like peptides or salts thereof as al-adrenergic receptor antagonists and vasorelaxants, nitric oxide-boosting agents, anti-thrombotic agents, anti-atherosclerotic agents, as protective agents against doxorubicin-induced cardiotoxicity, anti-ageing and adaptogenic agents, nutraceuticals, health supplements, or cosmetic ingredients. | 2022-04-07 |
20220106368 | IMMUNOGENIC FRAGMENT PEPTIDE OF EN2 PROTEIN OR ANTIBODY COMPOSITION SPECIFICALLY RECOGNIZING SAME - The present invention relates to an immunogenic fragment peptide of an EN2 protein or an antibody composition specifically recognizing the same. In the present invention, EN2 protein can be quantified through a method of specifically recognizing the peptide. Also, an antibody prepared using the peptide has vastly superior detection sensitivity compared to existing EN2 protein antibodies and thus can be useful in a diagnostic agent for diagnosing prostate cancer. | 2022-04-07 |
20220106369 | IMMUNOGENIC FRAGMENT PEPTIDE OF EN2 PROTEIN OR ANTIBODY COMPOSITION SPECIFICALLY RECOGNIZING SAME - The present invention relates to an immunogenic fragment peptide of an EN2 protein or an antibody composition specifically recognizing the same. In the present invention, EN2 protein can be quantified through a method of specifically recognizing the peptide. Also, an antibody prepared using the peptide has vastly superior detection sensitivity compared to existing EN2 protein antibodies and thus can be useful in a diagnostic agent for diagnosing prostate cancer. | 2022-04-07 |
20220106370 | VARIANT SURVIVIN VACCINE FOR TREATMENT OF CANCER - The invention concerns a variant (double mutant form) of the survivin polypeptide; nucleic acid molecules encoding the survivin variant; antigen presenting cells (APCs) such as dendritic cells, or APC precursors, comprising the variant survivin polypeptide or encoding nucleic acid sequence; and methods for treating a malignancy, such as myeloma, or for inducing an immune response, utilizing a variant survivin polypeptide, nucleic acid molecule, or APC. | 2022-04-07 |
20220106371 | MODIFIED RECOMBINANT HUMAN NERVE GROWTH FACTOR AND METHOD FOR PREPARING THE SAME - A modified recombinant human nerve growth factor (modified rhNGF) is obtained from the reaction between a polymer of formula A and an rhNGF. The polymer of formula A is an N-disubstituted amino acetamino aldehyde derivative. Experimental results have shown that the modified rhNGF has a higher in vivo plasma concentration and a longer in vivo half-life than when the rhNGF is not modified or is modified by monomethoxy polyglycol, and that the modified rhNGF preserves the original activity of the unmodified rhNGF. Moreover, the method of preparing the modified rhNGF is low-cost, and the modified products are highly consistent. | 2022-04-07 |
20220106372 | METHODS, COMPOSITIONS AND USES THEREOF FOR REVERSING SACROPENIA - Exemplary methods, compositions and uses thereof can be provided for preventing, reducing and/or treating loss of muscle function. In particular, e.g., it is possible to administer to a subject a pharmaceutical composition comprising a therapeutically effective amount of an agent that enhances Interleukin-6 (IL) release during exercise, and optionally a pharmaceutically acceptable carrier or excipient. | 2022-04-07 |
20220106373 | IL-10 VARIANT MOLECULES AND METHODS FOR TREATING INFLAMMATORY DISEASE AND ONCOLOGY - The application relates to compositions or formulations comprising variant IL-10 molecules, fusion proteins, and chimeric proteins thereof useful for the treatment of cancer, inflammatory diseases or disorders, and autoimmune diseases or disorders. | 2022-04-07 |
20220106374 | NOVEL INTERLEUKIN-15 (IL-15) FUSION PROTEINS AND USES THEREOF - The present disclosure provides novel and improved IL-15 fusion proteins for use in the treatment of cancer and other disorders. In various embodiments, the fusion proteins of the invention have two functional domains: an IL-15/IL-15RαSushi domain (also referred to herein as an “IL-15/IL-15RαSushi complex”) and an Fc domain, each of which can take different forms, and configured such that the IL-15 is fused to the C-terminal of the Fc domain and co-expressed and non-covalently complexed with IL-15RαSushi. Importantly, the fusions proteins of the present invention address several of the limitations observed with the IL-15 therapeutics evaluated to date; specifically, the fusion proteins demonstrate extended the half-life of IL-15 in vivo, and demonstrate superior preclinical activity compared to rIL-15 or related cytokine therapeutics. | 2022-04-07 |
20220106375 | MULTIMERIZATION OF IL-15/IL-15R-ALPHA-FC COMPLEXES TO ENHANCE IMMUNOTHERAPY - The present disclosure relates generally to complexes comprising an interleukin-15 (“EL-15”) polypeptide chain non-covalently bonded to an IL-15 receptor α-Fc fusion polypeptide (“IL-15Rα-Fc”), and multimers (e.g., trimers) thereof. The complexes of the present technology are useful in methods for enhancing immune cell function and immunotherapy in a patient in need thereof. Also provided herein are methods for preventing or treating a disease or condition in which enhancing IL-15-mediated function is beneficial (such as cancer, infectious diseases, immunodeficiencies and leukopenia) in a patient in need thereof. | 2022-04-07 |
20220106376 | METHODS, COMPOSITIONS AND USES THEREOF FOR REVERSING SACROPENIA - Exemplary methods, compositions and uses thereof can be provided for preventing, reducing and/or treating loss of muscle function. In particular, e.g., it is possible to administer to a subject a pharmaceutical composition comprising a therapeutically effective amount of an agent that enhances Interleukin-6 (IL) release during exercise, and optionally a pharmaceutically acceptable carrier or excipient. | 2022-04-07 |
20220106377 | COMPOSITIONS AND METHODS FOR T-CELL RECEPTOR GENE ASSEMBLY - Provided herein are compositions and methods for assembling nucleic acid sequences encoding T-cell receptors. | 2022-04-07 |
20220106378 | T-CELL MODULATORY ANTIGEN-PRESENTING POLYPEPTIDES AND METHODS OF USE THEREOF - The present disclosure provides T-cell modulatory antigen-presenting polypeptides, including single-chain antigen-presenting polypeptides and multimeric antigen-presenting polypeptides. The present disclosure provides nucleic acids comprising nucleotide sequences encoding T-cell modulatory antigen-presenting polypeptides of the present disclosure, as well as cells genetically modified with the nucleic acids. A T-cell modulatory antigen-presenting polypeptide of the present disclosure is useful for modulating activity of a T cell. Thus, the present disclosure provides compositions and methods for modulating the activity of T cells, as well as compositions and methods for treating persons who have autoimmune disorders. | 2022-04-07 |
20220106379 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST ESOPHAGEAL CANCER AND OTHER CANCERS - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2022-04-07 |
20220106380 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST ESOPHAGEAL CANCER AND OTHER CANCERS - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2022-04-07 |
20220106381 | CD154 PEPTIDES AND METHODS OF INHIBITING CD40 INTERACTIONS WITH CD154 - The present invention provides methods and materials for treating and preventing autoimmune diseases. In particular, the present invention relates to the discovery that small peptides are capable of interacting with CD40, thereby interfering with the ability of CD40 to interact with CD154, which is important in inflammation. The present invention also relate to the use of such peptides in reducing the inflammatory response, and in particular, the autoimmune inflammatory response. The present invention also relates to the use of such short peptides to prevent or reverse autoimmune disease, and particular, diabetes, in individuals suffering from such disease. It also relates to methods and materials for detecting T-cells that express CD40 (Th40 cells). Also provided are kits for reducing inflammation, treating autoimmune diseases, or detecting Th40 cells. | 2022-04-07 |
20220106382 | BETA-ARRESTIN MUTANTS - The invention relates to the field of arrestin mutants, especially mutants of beta-arrestin, a complex of the mutant beta-arrestin and a G-protein-coupled receptor (GPCR), and a vector encoding the mutant beta-arrestin. | 2022-04-07 |
20220106383 | THROMBIN CLEAVABLE LINKER WITH XTEN AND ITS USES THEREOF - The present invention provides a chimeric molecule comprising a VWF protein fused to a heterologous moiety via a VWF linker. The invention provides an efficient VWF linker that can be cleaved in the presence of thrombin. The chimeric molecule can further comprise a polypeptide chain comprising a FVIII protein and a second heterologous moiety, wherein the chain comprising the VWF protein and the chain comprising the FVIII protein are associated with each other. The invention also includes nucleotides, vectors, host cells, methods of using the chimeric proteins. | 2022-04-07 |
20220106384 | PEPTIDES INHIBITING KLK1, KLK4, OR KLK4 AND KLK8 - A novel peptide which comprises an amino acid sequence represented by SEQ ID NO: 23, and specifically inhibits the protease activity of a target molecule. | 2022-04-07 |
20220106385 | USE OF MODIFIED HIV-1 FOR GENERATING FULLY HUMAN ANTIBODIES - The present invention provides highly efficient methods, and compositions related thereto, for generating high titer human antibodies or antibody fragments thereof in a mammalian subject. The methods comprise administering a virus or virus-like particle to a mammal comprising heterologous immune cells and isolating a population of immunoglobulin-producing cells from the mammal, thereby producing the antibodies or antibody fragments thereof. | 2022-04-07 |
20220106386 | 14-3-3 ETA Antibodies and Uses Thereof for the Diagnosis and Treatment of Arthritis - The invention provides anti-14-3-3 eta antibodies that specifically bind to the human 14-3-3 eta protein isoform in its natural configuration while exhibiting selectivity over human 14-3-3 alpha, beta, delta, epsilon, gamma, tau, and zeta protein isoforms. Methods, kits and pharmaceutical compositions comprising said specific anti-14-3-3 eta antibodies are further provided for the diagnosis and treatment of arthritis. | 2022-04-07 |
20220106387 | ANTIBODIES TO PYROGLUTAMATE AMYLOID-B AND USES THEREOF - The invention provides antibodies or antigen binding fragments thereof that bind to 3pE Aβ and methods of making and using the antibodies or antigen binding fragments thereof, including use for formulations, administration and kits. The antibody and antigen binding fragments thereof and methods disclosed are useful for diagnosis, prognosis and treatment of Alzheimer's disease or other β-amyloid-related diseases. | 2022-04-07 |
20220106388 | HIGH VISCOSITY MACROMOLECULAR COMPOSITIONS FOR TREATING OCULAR CONDITIONS - Anti-angiogenesis compositions, and methods of using such compositions, useful for injection into the vitreous of human eyes are provided. Such compositions include MAAC solutions or particles present in a therapeutically effective amount, a viscosity-inducing component, and an aqueous carrier component. The compositions have viscosities at about 25° C. of at least about 10 cps or about 100 cps at a shear rate of 0.1/second. In a preferred embodiment, the viscosity at 25° C. is in the range of from about 80,000 cps to about 300,000 cps. | 2022-04-07 |
20220106389 | MULTI-TARGETING FUSION PROTEIN FOR BLOCKING THE GROWTH OF VASCULAR ENDOTHELIAL CELLS AND ACTIVATING T CELLS AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME - The present invention provides a multi-targeting fusion protein that blocks the growth of vascular endothelial cells and activates T cells, which comprises (i) a vascular endothelial cell growth inhibitory domain; (ii) an immunoglobulin Fc domain; and (iii) CD80 extracellular domain (ECD). The present invention also provides a polynucleotide encoding the multi-targeting fusion protein, a vector containing the polynucleotide, a host cell comprising the polynucleotide or the vector, and pharmaceutical composition comprising the multi-targeting fusion protein and an anti-PD-1 antibody. The multi-targeting fusion protein and pharmaceutical composition of the present invention can treat or prevent cancerous diseases in individuals. | 2022-04-07 |
20220106390 | METHODS FOR TREATING METABOLIC DISEASES BY INHIBITING MYOSTATIN ACTIVATION - The present invention relates to antibodies, or antigen-binding fragments thereof, that specifically bind proMyostatin and/or latent Myostatin, and methods and uses thereof for treating metabolic diseases. | 2022-04-07 |
20220106391 | ANTI-NGF ANTIBODIES AND METHODS OF USE THEREOF - The present disclosure encompasses novel anti-NGF antibodies, antigen binding proteins and polynucleotides encoding the same. The disclosure further provides use of the novel antibodies, antigen binding proteins and/or nucleotide of the invention for the treatment and/or prevention of NGF related disorders, particularly in for the management of pain. | 2022-04-07 |
20220106392 | ALBUMIN BINDING DOMAIN FUSION PROTEINS - Compositions that include an albumin binding domain and a fusion partner (e.g., a cytokine or a binding moiety) are provided. Such therapeutics have increased serum half-life and find use in applications where one or more such therapeutics are needed, for example, in oncology applications. | 2022-04-07 |
20220106393 | ANTI-CD147 ANTIBODY - An object of the present invention is to provide a novel anti-CD147 antibody exhibiting potent antitumor efficacy and having excellent safety. Another object of the present invention is to provide a pharmaceutical product comprising such an antibody. Another object of the present invention is to provide a method for treating tumors using the antibody or the pharmaceutical product, for example. The present invention provides a CD147-specific antibody that activates CD147 and exhibits high antitumor efficacy. The present invention provides the anti-CD147 antibody that exhibits high antitumor efficacy independent of effector functions. The present invention provides a pharmaceutical composition comprising such an anti-CD147 antibody. The present invention provides a method for treating tumors using such an anti-CD147 antibody and/or pharmaceutical composition. | 2022-04-07 |
20220106394 | Antitumor Agent - Provided is an antitumor agent targeting SIRPα, which inhibits binding between CD47 and SIRPα, the antitumor agent being more effective. The present invention also provides an antitumor agent capable of more effectively exhibiting an antitumor effect when used in combination with an immune checkpoint inhibitor or an antibody drug. The antitumor agent includes as an active ingredient a substance that molecularly targets an IgV domain, which is an extracellular domain of SIRPα. The antitumor agent of the present invention, including as an active ingredient a substance that molecularly targets an IgV domain of SIRPα protein, activates M1-type macrophages, which have cytotoxicity to cancer cells, and immunocompetent cells to provide an effective antitumor effect. Further, the antitumor agent can effectively exhibit an antitumor action not only on cancer cells expressing SIRPα on a cell surface but also on cancer cells not expressing the SIRPα when used in combination with, for example, an immune checkpoint inhibitor and/or an antibody drug that specifically reacts with a cancer antigen and has ADCC and ADCP activities. | 2022-04-07 |
20220106395 | ANTI-IL1RAP ANTIBODIES AND METHODS OF USE THEREOF - The present invention provides binding proteins, such as antibodies and antigen-binding fragments, which specifically bind to human interleukin-1 receptor accessory protein (hu-IL1RAP) and fully block the IL-1, IL-33, and IL-36 intracellular signaling pathways. Compositions comprising such binding proteins and methods of making and using such binding proteins are also provided. | 2022-04-07 |
20220106396 | Anti Human Interleukin-1 Receptor Accessory Protein (IL1 RAP) Antibodies and Uses Thereof - The present invention provides an antibody or an antigen-binding fragment thereof with binding specificity for human interleukin-1 receptor accessory protein (IL1RAP) wherein the antibody or antigen-binding fragment is capable of inhibiting the binding of antibody ‘CAN04’ to human ILIRAP. The invention further provides the use of such antibodies or an antigen-binding fragments in the treatment and/or diagnosis of IL-1 associated diseases and conditions, including cancers such as acute myeloid leukemia and melanoma. | 2022-04-07 |
20220106397 | Multivalent and Multispecific OX40-Binding Fusion Proteins - This invention relates generally to molecules that specifically engage OX40, a member of the TNF receptor superfamily (TNFRSF). More specifically this invention relates to multivalent and multispecific molecules that bind at least OX40. | 2022-04-07 |
20220106398 | ANTI-GITR ANTIGEN-BINDING DOMAINS AND USES THEREOF - This disclosure provides an antibody or antigen-binding fragment or derivative thereof that specifically binds to glu-cocorticoid-induced TNF receptor (GITR). Also provided are polynucleotides encoding the antibody or antigen-binding fragment or derivative thereof and vectors and host cell comprising said polynucleotides. This disclosure further provides methods for producing and/or using an antibody or antigen-binding fragment or derivative thereof that specifically binds to glucocorticoid-induced TNF re-ceptor (GITR). | 2022-04-07 |
20220106399 | MULTIMERIC CD40 BINDING MOLECULES AND USES THEREOF - This disclosure provides dimeric, pentameric, and hexameric CD40 agonist binding molecules and methods of using such binding molecules to induce anti-tumor immunity. | 2022-04-07 |
20220106400 | ANTIBODIES COMPRISING MODIFIED HEAVY CONSTANT REGIONS - Provided herein are heavy chain constant regions (referred to as “modified heavy chain constant regions”), or functionally equivalent fragments thereof, that (i) enhance biological properties of antibodies relative to the same antibodies in unmodified form or (ii) reduce effector function. An exemplary modified heavy chain constant region includes an IgG2 hinge and three constant domains (i.e., CH1, CH2, and CH3 domains), wherein one or more of the constant region domains are of a non-IgG2 isotype (e.g., IgG1, IgG3 or IgG4). The heavy chain constant region may comprise wildtype human IgG domain sequences, or variants of these sequences. Also provided herein are methods for enhancing certain biological properties of antibodies that comprise a non-IgG2 hinge, such as internalization, agonism and antagonism, wherein the method comprises replacing the non-IgG2 hinge of the antibody with an IgG2 hinge. | 2022-04-07 |
20220106401 | ANTI-EpCAM ANTIBODIES, COMPOSITIONS COMPRISING ANTI-EpCAM ANTIBODIES AND METHODS OF MAKING AND USING ANTI-EpCAM ANTIBODIES - Provided herein are antibodies that selectively bind to EpCAM and its isoforms and homologs, and compositions comprising the antibodies. Also provided are methods of using the antibodies, such as therapeutic and diagnostic methods. | 2022-04-07 |
20220106402 | ANTIBODY - In one aspect, the present invention relates to an immunoglobulin E (IgE) for use in repolarizing macrophages from a first phenotype to an anti-tumor phenotype in the treatment of cancer in a subject; wherein the first phenotype comprises a quiescent (M0) macrophage phenotype or an anti-inflammatory (M2a) macrophage phenotype; and the anti-tumor phenotype comprises a newly polarized macrophage phenotype characterized by expression of the following cytokines and chemokines: tumor necrosis factor alpha (TNFα); interferon-gamma (IFNγ); interleukin-1beta (IL-1β); interleukin-6 (IL-6); Regulated on Activation, Normal T cell Expressed and Secreted (RANTES or CCL5); and/or interleukin-10 (IL-10). | 2022-04-07 |
20220106403 | HETERODIMERIC ANTIBODIES THAT BIND MSLN AND CD3 - The present invention is directed to antibodies, including novel antigen binding domains and heterodimeric antibodies, that bind Mesothelin (MSLN). | 2022-04-07 |
20220106404 | CHIMERIC ANTIGEN RECEPTORS - Provided herein are therapeutic polypeptides, e.g., chimeric antigen receptors, able to direct an immune cell, e.g., a T lymphocyte to a target antigen, and able to cause the T cell to proliferate or to kill cells displaying the antigen when the antigen binds to the polypeptide, wherein the polypeptides comprise a transmembrane domain from a T cell co-inhibitory protein such as CTLA4 or PD-1. Also provided herein are T lymphocytes expressing the polypeptides, and use of such T lymphocytes to treat diseases such as cancer. | 2022-04-07 |
20220106405 | ANTI-MATRIX METALLOPROTEINASE 7 (MMP-7) INHIBITORY ANTIBODY AND USES THEREOF - An antibody comprising an antigen recognition region which binds a catalytic site of MMP-7, having complementarity determining region (CDR) amino acid sequences as set forth in: SEQ ID NOs: 3 (CDR1), 4 (CDR2) and 5 (CDR3), sequentially arranged from N to C on a light chain of the antibody; and SEQ ID NOs: 6 (CDR1), 7 (CDR2) and 8 (CDR3), sequentially arranged from N to C on a heavy chain of the antibody. | 2022-04-07 |
20220106406 | POLYPEPTIDE DIRECTED AGAINST PROTEIN TYROSINE PHOSPHATASE 4A PROTEINS, AND COMPOSITIONS AND METHODS FOR USE THEREOF - A protein tyrosine phosphatase 4A (PTP4A or PRL) targeting amino acid molecule is provided. The PRL targeting amino acid molecule includes an amino acid sequence according to one or more of NB91 (SEQ ID NO: 1), NB 13 (SEQ ID NO: 2), NB90 (SEQ ID NO: 3), NB4 (SEQ ID NO: 4), NB7 (SEQ ID NO: 5), NB10 (SEQ ID NO: 6), NB16 (SEQ ID NO: 7), NB18 (SEQ ID NO: 8), NB29 (SEQ ID NO: 9), NB19 (SEQ ID NO: 10), NB84 (SEQ ID NO: 11), NB92 (SEQ ID NO: 12), NB23 (SEQ ID NO: 13), NB26 (SEQ ID NO: 14), NB28 (SEQ ID NO: 15), NB68 (SEQ ID NO: 16), or a variant thereof. Also provided herein are methods of making and using the PRL targeting amino acid molecule. | 2022-04-07 |
20220106407 | GLUCURONOXYLOMANNAN (GXM) RECEPTOR CHIMERIC ANTIGEN RECEPTORS AND USE THEREOF - Provided herein are chimeric antigen receptors (CARs) comprising a glucuronoxylomannan receptor antigen-binding domain. Further provided herein are immune cells expressing the GXMR-CARs as well as methods of their use in the treatment of cryptococcosis. | 2022-04-07 |
20220106408 | NOVEL BIOTIN-SPECIFIC MONOCLONAL ANTIBODY AND USE THEREOF - The present invention relates to a monoclonal antibody capable of binding to biotin. In one embodiment the monoclonal antibody according to the invention also does not bind to a biotin moiety on a biotinylated molecule, wherein the biotin moiety is attached to the molecule via the carbon atom of the carboxyl function of the valeric acid moiety of biotin. Also disclosed is a method for generation of an antibody as disclosed herein. The monoclonal antibody according to the invention is of specific use in a method for measuring an analyte in a sample, wherein a (strept)avidin/biotin pair is used to bind a biotinylated analyte specific binding agent to a (strept)avidin coated solid phase. | 2022-04-07 |
20220106409 | Multi-response Cellulose Nanocrystals-composite Film and Preparation Method Thereof - The disclosure discloses a multi-response cellulose nanocrystals-composite film and a preparation method thereof, belonging to the technical field of functional materials. The multi-response cellulose nanocrystals-composite film of the disclosure includes cellulose nanocrystals, a deep eutectic solvent and anthocyanins. The deep eutectic solvent is composed of choline chloride and biological sugar. A mass ratio of the choline chloride to the biological sugar is 1-20:1-6. A mass ratio of the cellulose nanocrystals to the deep eutectic solvent to the anthocyanins is 10:0-10:1, and the amount of the deep eutectic solvent is not 0. The preparation method of the composite film of the disclosure is simple and easy to operate, and has the advantages of mild conditions and short time consumption. The multi-response film prepared in the disclosure has humidity and pH detection functions, has the advantages of good flexibility, good reversibility, excellent stability, etc., and can be used as a flexible humidity and pH sensor. | 2022-04-07 |
20220106410 | HYDROXYPROPYL METHYL CELLULOSE ACETATE SUCCINATE, METHOD FOR PRODUCING THE SAME, AND COMPOSITION FOR HOT-MELT EXTRUSION - There is provided a method for efficiently produce hydroxypropyl methyl cellulose acetate succinate (HPMCAS) having excellent flowability, where acetic acid in a reaction product mixture subjected to a wash and recovery step can be reduced. More specifically, there is provided a method for producing HPMCAS including an esterification step of esterifying hydroxypropyl methyl cellulose (HPMC) with acetic anhydride and succinic anhydride in acetic acid as a solvent to obtain a reaction product solution containing HPMCAS; a water addition step of adding water to the reaction product solution to obtain a water-added reaction product solution; an acetic acid removal step of removing at least a portion of both the solvent acetic acid and acetic acid derived from the acetic anhydride from the water-added reaction product solution to obtain a mixture having an acetic acid content reduced; and a wash and recovery step of washing the mixture and recovering the HPMCAS. | 2022-04-07 |
20220106411 | PROCESS FOR PRODUCING A CROSSLINKED CELLULOSE ETHER - A process for producing a crosslinked cellulose ether including contacting an activated cellulose material with (i) an aqueous crosslinking agent emulsion, wherein the aqueous crosslinking agent emulsion is a mixture of (ia) at least one crosslinking agent; (ib) water; and (ic) any other optional components desired; and (ii) at least one etherification reagent; wherein the aqueous crosslinking agent emulsion (i) and the at least one etherification reagent (ii) react with the activated cellulose material to form the crosslinked cellulose ether; and a crosslinked cellulose ether produced by the above process. | 2022-04-07 |
20220106412 | COMPOSITE PARTICLES AND METHOD FOR PRODUCING COMPOSITE PARTICLES - A composite particle comprising: a core particle containing at least one type of polymer; and micronized cellulose that has an anionic functional group, is inseparably bonded to the core particle, and is disposed on a surface of the core particle, wherein an organic onium cation or an ammonium ion is bonded to at least a part of the micronized cellulose. | 2022-04-07 |
20220106413 | CORN FIBER PROCESSING SYSTEM AND WET MILLED CORN STARCH PROCESSING SYSTEM USING SAME - The embodiments of the present application provide a maize fiber processing system and a maize wet-milled starch processing system using same. The maize fiber processing system comprises a pressure curved screen group, a fiber washing sink group, an enzyme preparation adding device and an external enzyme reaction tank, wherein the external enzyme reaction tank is used for receiving screen overflow from a middle stage of pressure curved screen or fiber slurry in a middle stage of fiber washing sink and providing a place for enzyme reaction, thereby extending reaction time of enzyme participation. In addition, the reaction efficiency of the enzyme preparation can be further improved by means of controlling the fiber dry substance concentration in the external enzyme reaction tank. | 2022-04-07 |
20220106414 | NATURAL HYDROCOLLOID SYSTEMS FOR PET FOOD COMPOSITIONS, PET FOOD COMPOSITIONS COMPRISING SAME, AND PREPARATIONS THEREOF - A natural hydrocolloid system can be used in, e.g., pet food compositions. Another aspect of the present disclosure is pet food compositions comprising such a natural hydrocolloid system, and preparation methods thereof. The hydrocolloid system can use blends of fruit fibers, such as citrus and apple fibers, and/or plant-based polysaccharides, such as | 2022-04-07 |
20220106415 | CARBOXYL GROUP-CONTAINING NITRILE RUBBER - A carboxyl group-containing nitrile rubber having an iodine value of 120 or less, wherein the content of sodium is 1500 ppm by weight or less, the total content of calcium, magnesium, and aluminum is 350 ppm by weight or less, and the storage elastic modulus at 140° C. is 350 kPa or more. | 2022-04-07 |
20220106416 | MODIFIED (CO)POLYMER, METHOD FOR PREPARING THEREOF AND USE OF THE SAME - The invention relates to the field of modified diene-containing (co)polymers, in particular, to modified butadiene-styrene copolymers that can be used as flame retardants for polymer compositions based on expandable polystyrene. In particular, the invention relates to a modified diene-containing (co)polymer, a method for preparing thereof and the use of the same as a flame retardant for expandable polystyrene. The modified diene-containing (co)polymer according to the invention is characterized by a high heat resistance, in particular, a 5% weight loss temperature of at least 180° C., a molecular weight of at least 1500 g/mol, and a halogen content of at least 35 wt. % based on the total weight of the (co)polymer. | 2022-04-07 |
20220106417 | POLYMERIZATION PHOTOINHIBITOR - Provided herein is technology relating to polymerization and producing polymers and particularly, but not exclusively, to methods, systems, and compositions for producing articles using three-dimensional printing and for improving control of polymerization using a polymerization photoinhibitor having fast back reaction kinetics such as hexaarylbiimidazole compounds and bridged hexaarylbiimidazole compounds. | 2022-04-07 |
20220106418 | HIGH-PRESSURE POLYMERIZATION PROCESS OF ETHYLENICALLY UNSATURATED MONOMERS IN A POLYMERIZATION REACTOR - A process for polymerizing ethylene in a high-pressure polymerization system having a continuously operated polymerization reactor and a reactor blow down system having an emergency valve, a reactor blow down vessel containing an aqueous medium and a reactor blow down dump vessel, wherein the process includes the steps of monitoring the polymerization system for a disturbance, opening the emergency valve when a disturbance occurs to allow the content of the polymerization system to expand into the reactor blow down vessel, contacting the content of the polymerization system in the reactor blow down vessel with the aqueous medium to obtain an aqueous polymer slurry, separating the polymer slurry and gaseous components, and transferring the polymer slurry to the reactor blow down dump vessel. | 2022-04-07 |
20220106419 | B-STAGEABLE AQUEOUS BINDER COMPOSITIONS - An aqueous binder composition is disclosed that includes 5.0% by weight to 50.0% by weight of a monomeric polyol having at least four hydroxyl groups, based on the total solids content of the aqueous binder composition; and at least 50.0% by weight of a cross-linking agent comprising a polymeric polycarboxylic acid having at least two carboxylic acid groups, based on the total solids content of the aqueous binder composition. The aqueous binder composition includes a ratio of molar equivalents of carboxylic acid groups to hydroxyl groups is between 0.15/1.0 and 2.23/1 and has a pH of 2.2 to 4.0 and a viscosity at 40% solids and 25° C. of 10 cP to 60 cP. | 2022-04-07 |
20220106420 | CURABLE RESIN COMPOSITION AND CURED PRODUCT THEREOF - An aspect of the present invention provides a curable resin composition containing (A) a vinyl sulfide compound represented by general formula (1) and (B) an isocyanate compound having an isocyanate group. | 2022-04-07 |
20220106421 | Method For Producing Polydienes With Reduced Cold Flow - A process for preparing a polydiene having increased viscosity and reduced cold flow that includes polymerizing a conjugated diene monomer in the presence of a lanthanide-containing compound to form an intermediate polymer, and then adding a non-organometallic trimellitate ester compound as a coupling agent to raise the viscosity of the intermediate polymer. The coupling agent is added to the intermediate polymer mixture in an amount of about 0.01 to about 0.15 parts per hundred monomer (phm) of the starting monomer amount. | 2022-04-07 |
20220106422 | Catalyst Systems and Processes for Poly Alpha-Olefin Having High Vinylidene Content - A process for making a poly alpha-olefin (PAO) having a relatively high vinylidene content (or combined vinylidene and tri-substituted vinylene content) and a relatively low vinyl and/or di-substituted vinylene content, as well as a relatively low molecular weight. The process includes: contacting a feed containing a C | 2022-04-07 |
20220106423 | IODINE TRANSFER POLYMERIZATION METHOD AND COMPOSITIONS THEREFROM - Iodine transfer radical polymerization of an ethylenically unsaturated monomer comprising (meth)acrylic acid, salt thereof, or combination thereof, in the presence of a radical polymerization initiator, an organoiodide, and a solvent, is a useful method for making (meth)acrylic acid polymers. The amounts of components utilized can be 2 to 100 equivalents of acrylic acid and 2 to 100 equivalents of sodium acrylate, both dissolved in water to form a 15 to 50 weight percent solution, based on the total weight of the acrylic acid, sodium acrylate, and water; 0.05 to 1 equivalent of an azo polymerization initiator, 1 equivalent of an organoiodide; and 0 to 3 equivalents of an iodide salt. (Meth)acrylic acid polymer solutions are made by these methods. The (meth)acrylic polymers are useful as dispersants. | 2022-04-07 |
20220106424 | HYDROGEL COMPOSITION FOR A SEMI-RIGID ACOUSTIC COUPLING MEDIUM IN ULTRASOUND IMAGING - Disclosed are compositions and articles for a semi-rigid hydrogel material that provides an acoustic coupling medium for ultrasound diagnostic and treatment techniques. In one aspect, a hydrogel material for an acoustic coupling medium includes a sodium alginate block copolymer, a dimethylacrylamide monomer, and water. In some implementations, the sodium alginate block copolymer is present in an amount of about 0.5 wt % to about 25 wt %, the dimethylacrylamide monomer is present in an amount of about 1 wt % to about 40 wt %, and the water is present in an amount of at least about 50 wt % of the total weight of the hydrogel composition. | 2022-04-07 |
20220106425 | COMPOSITION AND METHOD FOR LAMINATION OF SILICON DOMINANT ELECTRODES - Disclosed are maleic anhydride-grafted cyclic olefin copolymers, methods for preparing maleic anhydride-grafted cyclic olefin copolymers, low temperature methods for laminating anodes comprising the maleic anhydride-grafted cyclic olefin copolymers, and anodes and alkali ion batteries that comprise the maleic anhydride-grafted cyclic olefin copolymers. | 2022-04-07 |
20220106426 | COPPER-CLAD LAMINATE PLATE, RESIN-ATTACHED COPPER FOIL, AND CIRCUIT BOARD USING SAME - A copper-clad laminate includes an insulating layer formed of a cured product of a resin composition and a surface treated copper foil in contact with the insulating layer, in which the resin composition contains a compound having at least one group specified in the present application and a crosslinking type curing agent; and the surface treated copper foil is a surface treated copper foil including a finely roughened particle treatment layer of copper on at least one surface side of copper foil. | 2022-04-07 |
20220106427 | STORAGE-STABLE PIGMENTED ISOCYANATE GROUP-CONTAINING FORMULATIONS WITH ISOCYANATE GROUP-CONTAINING GRINDING RESIN AND USE THEREOF - The invention relates to storage-stable pigmented formulations containing isocyanate groups, comprising at least one pigment a., at least one component b. containing isocyanate groups, at least one wetting agent and/or dispersant c., at least one isocyanate group-containing grinding resin d. and optionally solvents, wherein the formulation has a viscosity increase of less than 500% after storage at 50° C. over a period of at least 3 days. The invention also relates to the preparation of such formulations and to the use thereof | 2022-04-07 |
20220106428 | POLYETHER COMPOSITION, LOW VOC POLYURETHANE FOAM AND PREPARATION METHOD THEREFOR - A polyether composition for a polyurethane foam is provided, comprising a polyether polyol and a polyether carbonate polyol that has a primary hydroxyl group molar content of not less than 40 mol %. A method for preparing a polyurethane foam is further provided, comprising the following steps: preparing a mixture by preheating and melting the polyether composition for a polyurethane foam, a foaming agent, a chain extender, a catalyst, a pore-forming agent and a foam stabilizer, and mixing well; cooling the mixture; and performing a polymerization reaction by adding an isocyanate to the cooled mixture and mixing, thus obtaining a polyurethane foam product. The use of the polyether carbonate polyol with the primary hydroxyl group molar content of not less than 40 mol % overcomes the defects of unstable performance of polyurethane and poor mechanical properties of products when the VOC content of the polyurethane foam is reduced by adding additives in the prior art. | 2022-04-07 |
20220106429 | Anhydride Catalysts for Urethane and Urethane-Urea Systems - Polyurethane and polyurethane-urea compositions are prepared by amine cure under catalyzed reaction conditions. The curing reaction is performed with an acid anhydride based curing catalyst which is added to a prepolymer and then subsequently reacted with an amine based curative. | 2022-04-07 |
20220106430 | AMINE CATALYSTS FOR POLYURETHANE FOAMS - The invention provides polyurethane and polyisocyanurate foams and methods for the preparation thereof. More particularly, the invention relates to open-celled, polyurethane and polyisocyanurate foams and methods for their preparation. The foams are characterized by a fine uniform cell structure and little or no foam collapse. The foams are produced with a polyol premix composition which comprises a combination of a hydrohaloolefin blowing agent, a polyol, a silicone surfactant, and a sterically hindered amine catalyst. | 2022-04-07 |
20220106431 | ISOCYANATE-TERMINATED PREPOLYMERS FOR THE PRODUCTION OF INTEGRAL POLYURETHANE FOAMS - A method for producing a prepolymer for the production of an integral polyurethane foam is provided. The prepolymer is or can be obtained by reaction of a composition that contains the following components: component A containing a polyoxymethylene-polyoxyalkylene block copolymer having a hydroxyl number of 20 mg KOH/g to 200 mg KOH/g as component Al, component B containing di- and/or polyisocyanates with an NCO content of 15 to 45 wt.-% relative to component B, 0.04 to 1.0 wt.-%, relative to the composition, a proton acid as component C, and optionally a component D that contains auxiliary agents, at a characteristic number of 450 to 850. The invention further relates to the prepolymer obtained by the method, to an integral polyurethane foam based on the prepolymer, and to the use thereof. | 2022-04-07 |
20220106432 | SHAPED FLEXIBLE PU FOAM ARTICLES - Shaped flexible PU foam articles, preferably mattresses and/or cushions, may use a flexible polyurethane foam obtained by reaction of at least one polyol component and at least one isocyanate component in the presence of at least one blowing agent and one or more catalysts that catalyze the isocyanate-polyol and/or isocyanate-water reactions and/or isocyanate trimerization and further additives, wherein the additives include one or more organic esters. | 2022-04-07 |
20220106433 | FLEXIBLE POLYURETHANE FOAMS WITH HIGH WATER ABSORPTION CAPACITY - Described herein is a process for producing a hydrophilic flexible polyurethane foam. Also described herein is a flexible polyurethane foam obtainable by such a process and a method of using such a flexible polyurethane foam for treating wounds. | 2022-04-07 |
20220106434 | Foamable, multi-component composition which forms an insulation layer, and use thereof - A foamable, multi-component composition based on polyurea and/or polyurethane forms an insulation layer. The composition can be used for foaming openings, cable and pipe feedthroughs, and joints for the purpose of fire protection. | 2022-04-07 |
20220106435 | EPOXY RESIN SOLUTION - The present invention provides an epoxy resin solution, from which an epoxy resin-cured product adequately excellent in heat-resisting properties and dielectric properties can be obtained with adequately good working properties ensured. The present invention relates to an epoxy resin solution containing at least a curing agent and an epoxy resin mixed in an organic solvent, wherein the curing agent comprises an imide group-containing curing agent having 1-4 imide groups and 2-4 glycidyl group-reactive functional groups in a molecule. | 2022-04-07 |